IMC-002 is named as an intervention in 3 current clinical trials in our China and South Korea registers. 2 are recruiting patients now. The most common phase is Phase 1/2. The sponsor with the most trials is ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd (1). The most-studied condition is Systemic Lupus Erythematosus.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus
|
Phase 1/2 | Recruiting | ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd | China |
|
A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
NCT05276310 · ClinicalTrials.gov ↗ · Advanced Cancer
|
Phase 1 | Recruiting | ImmuneOncia Therapeutics Inc | South Korea |
|
IMM0306 in Combination With Lenalidomide vs Placebo in Combination With Lenalidomide in Patients With Relapsed/Refractory Follicular Lymphoma
NCT07355283 · ClinicalTrials.gov ↗ · Relapsed/Refractory Follicular Lymphoma
|
Phase 3 | Not yet open | ImmuneOnco Biopharmaceuticals (Shanghai) Inc | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd | 1 |
| ImmuneOncia Therapeutics Inc | 1 |
| ImmuneOnco Biopharmaceuticals (Shanghai) Inc | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 1 |
| Clinical trials in South Korea | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
3 current trials in our China and South Korea registers name IMC-002 (also registered as IMM0306) as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 3 trials are recruiting: 1 with sites in China and 1 with sites in South Korea. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd (1), ImmuneOncia Therapeutics Inc (1) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how IMC-002 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how IMC-002 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists IMC-002 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.